Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 Jan 19;12(1):e002442.
doi: 10.1136/bmjresp-2024-002442.

Lung function and onset of cardiometabolic diseases in the longitudinal Burden of Obstructive Lung Disease study

Collaborators, Affiliations
Multicenter Study

Lung function and onset of cardiometabolic diseases in the longitudinal Burden of Obstructive Lung Disease study

Christer Janson et al. BMJ Open Respir Res. .

Abstract

Introduction: Previous population-based studies, mainly from high-income countries, have shown that a higher forced vital capacity (FVC) is associated with a lower risk of developing cardiometabolic diseases. The aim of this study was to assess the longitudinal association between spirometry measures and the onset of cardiometabolic diseases across sites in low-income, middle-income and high-income countries.

Methods: The study population comprised 5916 individuals from 15 countries participating in the Burden of Obstructive Lung Disease baseline and follow-up assessments. Postbronchodilator forced expiratory volume in 1 s (FEV1), FVC and FEV1/FVC were measured at baseline. Participants who reported having doctor-diagnosed hypertension, diabetes, heart disease and stroke at follow-up but not at baseline were considered new cases of these diseases. The association between lung function and the onset of participant-reported cardiometabolic diseases was assessed in each site using regression models, and estimates were combined using random effects meta-analysis. Models were adjusted for sex, age, smoking, body mass index and educational level.

Results: Participants with greater per cent predicted FVC were less likely to have new-onset diabetes (OR per 10%=0.91, 95% CI 0.84 to 0.99), heart disease (OR per 10%=0.86, 95% CI 0.80 to 0.92) and stroke (OR per 10%=0.81, 95% CI 0.73 to 0.89) during the follow-up period (mean±SD 9.5±3.6 years). A greater percentage of FEV1 was associated with a lower risk of onset of heart disease and stroke. No significant association was found between FEV1/FVC and onset of reported cardiometabolic diseases, except for a higher risk of diabetes (OR per 10%=1.21, 95% CI 1.08 to 1.35) in participants with higher FEV1/FVC.

Conclusions: The findings of this study suggest that a low FVC is more important than a low FEV1/FVC as a risk factor for developing cardiometabolic diseases. The value of including FVC in risk score models to improve their precision in predicting the onset of cardiometabolic diseases should be explored.

Keywords: COPD epidemiology; Clinical Epidemiology; Lung Physiology.

PubMed Disclaimer

Conflict of interest statement

Competing interests: RN declares support from Astra Zenenca related to and the Norwegian Respiratory Society not related to the manuscript. AØR declares support from Boehringer Ingelheim and the Endowment of Timber Merchant A. Delphin and Wife unrelated to the manuscript. PGJB declares support from the Wellcome Trust related to the manuscript. AFSA declares support from the Colt Foundation not related to the manuscript. None of the other authors declare any conflicts of interest.

Figures

Figure 1
Figure 1. Study population of the Burden of Obstructive Lung Disease (BOLD) follow-up study.
Figure 2
Figure 2. Association between forced vital capacity expressed as per cent of predicted and onset of diabetes, heart disease and stroke. Adjusted OR* (95% CI) for 10 units change. The association was assessed in each site and combined by random effects meta-analyses. I2 values of 0%, 25%, 50% and 75% were considered no, low, moderate and high heterogeneity. *Adjusted for age, sex, smoke history, BMI and educational level baseline. BMI, body mass index.

Similar articles

Cited by

References

    1. Ställberg B, Janson C, Larsson K, et al. Real-world retrospective cohort study ARCTIC shows burden of comorbidities in Swedish COPD versus non-COPD patients. NPJ Prim Care Respir Med. 2018;28:33. doi: 10.1038/s41533-018-0101-y. - DOI - PMC - PubMed
    1. Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012;380:37–43. doi: 10.1016/S0140-6736(12)60240-2. - DOI - PubMed
    1. Triest FJJ, Studnicka M, Franssen FME, et al. Airflow Obstruction and Cardio-metabolic Comorbidities. COPD. 2019;16:109–17. doi: 10.1080/15412555.2019.1614550. - DOI - PMC - PubMed
    1. Kulbacka-Ortiz K, Triest FJJ, Franssen FME, et al. Restricted spirometry and cardiometabolic comorbidities: results from the international population based BOLD study. Respir Res. 2022;23:34. doi: 10.1186/s12931-022-01939-5. - DOI - PMC - PubMed
    1. Margretardottir OB, Thorleifsson SJ, Gudmundsson G, et al. Hypertension, systemic inflammation and body weight in relation to lung function impairment-an epidemiological study. COPD. 2009;6:250–5. doi: 10.1080/15412550903049157. - DOI - PMC - PubMed

Publication types

LinkOut - more resources